Analysis of Imaging Features From Patients Treated With Brol... | Clinical Trial | StuddyBuddy@endsection Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05657158

Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion

Conditions: Intraocular Inflammation, Retinal Vascular Occlusion

Sex: All
Ages: 18 Years – 105 Years
Enrollment: 198
Sponsor: Novartis Pharmaceuticals

Location: Switzerland

Summary

This non-interventional descriptive study was undertaken to better understand the most common imaging features associated with inflammation arising in the post-marketing setting when brolucizumab was prescribed in routine clinical practice.

Eligibility Criteria

Inclusion Criteria:participants with cases of RV and/or RO reported to Novartis Patient Safety following brolucizumab use in routine clinical practice for which images were provided to Novartis and read by the Reading Centre

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05657158). StuddyBuddy aggregates publicly available trial information.